Monoclonal antibodies interacting with cytokines associated with eosinophilia (e.g., IL-5, IL-33) are currently evaluated in clinical trials to treat eosinophilic COPD patients: Mepolizumab (anti-IL-5; NCT04075331), MEDI3506 (anti-IL-33; NCT04570657), REGN3500 (anti-IL-33; NCT04701983 and NCT04751487) and Astegolimab (anti-ST2; NCT03615040). This evidence concerns the gene IL33 and Increased total eosinophil count.